Valuation: Lite Strategy, Inc.

Market Cap 3.16Cr 2.83Cr 2.6Cr 2.36Cr 4.43Cr 299.56Cr 4.54Cr 31Cr 12Cr 158.11Cr 12Cr 12Cr 501.14Cr P/E 2025
-1.03x
P/E 2026 -0.45x
Enterprise Value 2.59Cr 2.32Cr 2.13Cr 1.93Cr 3.63Cr 245.51Cr 3.72Cr 25Cr 10Cr 129.58Cr 9.73Cr 9.52Cr 410.72Cr EV / Sales 2025
-
EV / Sales 2026 -
Free-Float
86.21%
Yield 2025 *
-
Yield 2026 -
1 day+7.47%
1 week-9.96%
Current month-7.14%
1 month-24.64%
3 months+5.99%
6 months-7.96%
Current year-21.21%
1 week 0.95
Extreme 0.95
1.22
1 month 0.95
Extreme 0.95
1.44
Current year 0.69
Extreme 0.6888
1.65
1 year 0.69
Extreme 0.6888
2.26
3 years 0.69
Extreme 0.6888
9
5 years 0.69
Extreme 0.6888
71
10 years 0.69
Extreme 0.6888
102.8
Manager TitleAgeSince
Chief Executive Officer 56 01/08/2024
Director TitleAgeSince
Chairman 75 01/08/2024
Director/Board Member 57 11/06/2013
Director/Board Member 56 14/11/2025
Date Insider Type Main position Quantity % Market Cap. Importance
12/02/26 Free

Chief Executive Officer

4,55,000 1.2374%
19/12/25 Buy

Director

70,000 0.1903%
18/12/25 Sell 6,90,611 1.8774%
Change 5-day change 1-year change 3-year change Capi.($)
+7.47%-9.96%-45.83%-85.39% 3.16Cr
-2.43%-4.38%+40.32%+55.64% 6.06TCr
-0.43%+3.56%+20.78%+96.80% 5.55TCr
+1.98%+0.90%+9.51%+74.06% 5.52TCr
+1.61%-3.30%+22.77%+33.16% 4.33TCr
-1.74%-3.02%+13.83%+93.17% 4.04TCr
+3.22%+4.30%+227.37%+776.49% 4.16TCr
-0.83%-4.06%+96.51%+85.36% 3.33TCr
-1.09%+0.69%+14.20%+45.26% 3.23TCr
-4.46%+9.98%-43.92%+320.28% 2.29TCr
Average +0.33%+2.05%+35.55%+149.48% 3.85TCr
Weighted average by Cap. -0.25%+2.15%+46.21%+160.99%

Financials

2025 2026
Net sales - -
Net income -1.59Cr -1.42Cr -1.31Cr -1.19Cr -2.23Cr -151.04Cr -2.29Cr -16Cr -6.28Cr -80Cr -5.98Cr -5.86Cr -252.68Cr -7.12Cr -6.36Cr -5.84Cr -5.3Cr -9.96Cr -673.99Cr -10Cr -70Cr -28Cr -355.73Cr -27Cr -26Cr -1.13TCr
Net Debt -1.8Cr -1.61Cr -1.48Cr -1.34Cr -2.52Cr -170.61Cr -2.58Cr -18Cr -7.1Cr -90Cr -6.76Cr -6.62Cr -285.42Cr -57.06L -50.98L -46.83L -42.53L -79.86L -54Cr -81.87L -5.59Cr -2.25Cr -29Cr -2.14Cr -2.1Cr -90Cr
Projected Income Statement - Annual - Lite Strategy, Inc.
Logo Lite Strategy, Inc.
Lite Strategy, Inc. is a pharmaceutical company focused on developed and differentiated cancer therapies. The Company's drug candidate pipeline includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, zandelisib, an oral, once-daily, selective PI3Kd inhibitor. CDK9 functions in cell cycle regulation, and its modulation in cancer and autoimmune diseases. It is a transcriptional regulator of the myeloid leukemia cell differentiation protein (Mcl-1). Zandelisib is an oral, once-daily, selective PI3Kd inhibitor that is developed for the treatment of indolent B-cell lymphomas. Its approach to pre-clinical drug development is to evaluate its drug candidates in combination with standard-of-care therapies to overcome known resistance mechanisms and address medical needs. It holds Litecoin (LTC) tokens as a primary asset as part of an institutional treasury. LTC is an open source, global payment network that is decentralized without any central authorities.
Employees
5
Date Price Change Volume
03/26/03 $1.040 +7.47% 1,90,024
02/26/02 $0.9677 -13.60% 7,29,804
30/26/30 $1.120 -4.27% 2,70,470
29/26/29 $1.170 -4.88% 3,41,052
28/26/28 $1.230 +6.49% 2,97,759

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Lite Strategy, Inc.
  1. Stock Market
  2. Stocks
  3. LITS Stock